Y-mAbs Therapeutics Inc - Company Profile
Powered by 
All the data and insights you need on Y-mAbs Therapeutics Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Y-mAbs Therapeutics Inc Strategy Report
- Understand Y-mAbs Therapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Y-mAbs Therapeutics Inc(Y-mAbs) is a clinical biopharmaceutical company that develops and commercializes novel antibody therapeutic products for cancer treatment. The company technologies include bispecific antibodies generated using the Y-BiClone platform and the SADA platform. Its pipeline products includes DANYELZA (naxitamab-gqgk), which targets tumors that express GD2, and omburtamab, which targets tumors that express B7-H3. DANYELZA is a humanized monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of in the bone or bone marrow stable disease to prior therapy and being evaluated for the treatment of other GD2-positive tumors. It also develops omburtamab, which is a novel murine monoclonal antibody targeting B7-H3. The Company is conducting Phase II clinical trials for the treatment of patients with first-line NB, third-line NB and relapsed osteosarcoma. It has a license and research collaboration agreement with Memorial Sloan-Kettering Cancer Center. Y-mAbs is headquartered in New York, the US.
Headquarters
United States of America
Address
230 Park Avenue, Suite 3350, New York, 10169
Website
www.ymabs.com
Telephone
1 212 8479841
No of Employees
100
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
YMAB (NASD)
Revenue (2022)
$84.8M
30%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
77.6%
(2022 vs 2021)
Market Cap*
$538.8M
Net Profit Margin (2022)
XYZ
82.8%
(2022 vs 2021)
* As of and is in US$
Y-mAbs Therapeutics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | Danyelza |
| Naxitamab (GD2) | |
| Omburtamab (B7-H3) | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Regulatory Approval | In October, the company announced that the U.S. Food and Drug Administration cleared the Investigational New Drug application for CD38-SADA. |
| 2023 | Regulatory Approval | In May, the company received marketing authorization for DANYELZA (naxitamab-gqgk) 40mg/10mL injection from the Brazilian Health Regulatory Agency, Agência Nacional de Vigilancia Sanitaria. |
| 2023 | Contracts/Agreements | In February, the company announced that the European Medicines Agency agreed to the Company's proposed Pediatric Investigation Plan ("PIP") for naxitamab. |
Competitor Comparison
| Key Parameters | Y-mAbs Therapeutics Inc | MacroGenics Inc | Cara Therapeutics Inc | APEIRON Biologics AG | Cellerant Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | Austria | United States of America |
| City | New York | Rockville | Stamford | Vienna | San Carlos |
| State/Province | New York | Maryland | Connecticut | Wien | California |
| No. of Employees | 100 | 339 | 55 | - | - |
| Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| James I. Healy | Chairman | Executive Board | 2017 | 58 |
| Thomas Gad | Chief Business Officer; Vice Chairman | Executive Board | 2023 | 53 |
| Michael Rossi | Chief Executive Officer; Director; President | Executive Board | 2023 | - |
| Bo Kruse | Executive Vice President; Secretary; Treasurer; Chief Financial Officer | Senior Management | 2015 | 51 |
| Joris Wiel Jan Wilms | Chief Operating Officer; Senior Vice President | Senior Management | 2017 | 49 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer